Junevity develops medicines targeting transcription factors to reverse diseases of aging.
Junevity has raised $10.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2026.
Junevity's investors include Goldcrest Capital, Godfrey Capital, AMOREPACIFIC Ventures.
Junevity is headquartered in San Francisco, United States.
Junevity develops medicines targeting transcription factors to reverse diseases of aging.
Junevity is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Junevity — Funding & Investors." VCBacked, September 29, 2026, https://www.vcbacked.co/company/junevity. Accessed October 13, 2026.
VCBacked. (2026). Junevity — Funding & Investors. Retrieved October 13, 2026, from https://www.vcbacked.co/company/junevity
{{cite web |title=Junevity — Funding & Investors |url=https://www.vcbacked.co/company/junevity |website=VCBacked |access-date=October 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated